Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02660996 · ClinicalTrials.gov registry record
Effectiveness of the Advocate Lutheran General Survivorship Center Programs
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 22
- Enrollment target
NCT02660996: Completed study, sponsored by Wake Forest University Health Sciences.
NCT02660996 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02660996 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
The objective of this observational study is to assess the effectiveness of the Advocate Lutheran General Survivorship Center's Programs by measuring the following outcomes of interest on participating patients: 1. Quality of life 2. Distress level 3. Satisfaction with the Survivorship Program General Hypothesis: Patients who participate in at least four classes in a two month period will have higher scores on the post-class satisfaction, quality of life, and distress surveys compared to their pre-class surveys.
Primary Outcome
Questionnaire that includes 36 questions and asks how patients feel their illness has impacted them and their lifestyle with scoring as noted.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-10-01 |
| Est. Completion | 2017-08-14 |
What the finished NCT02660996 record still lists
NCT02660996 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02660996 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02660996 about?
NCT02660996 is a clinical study titled "Effectiveness of the Advocate Lutheran General Survivorship Center Programs". The objective of this observational study is to assess the effectiveness of the Advocate Lutheran General Survivorship Center's Programs by measuring the following outcomes of interest on participating patients: 1. Quality of life 2. Distress level 3. Satisfaction with the Survivorship Program Gen...
What is the current status of trial NCT02660996?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2016-10-01. Estimated completion is 2017-08-14.
Who is sponsoring clinical trial NCT02660996?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI